Novozymes stock

NSIS.B · Nasdaq Copenhagen · DKK

kr 455.60Change from previous close: −0.72%Absolute change: −kr 3.30

Close · November 16, 2026

Price history

+11.37% over the period

1 year: from kr 409.10 (November 17, 2025) to kr 455.60 (November 16, 2026), +11.37%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026kr 455.60
October 30, 2026kr 462.00
September 30, 2026kr 419.50
August 31, 2026kr 462.40
July 31, 2026kr 422.00
June 30, 2026kr 412.90
May 29, 2026kr 372.50
April 30, 2026kr 390.90
March 31, 2026kr 382.50
February 27, 2026kr 375.50
January 30, 2026kr 385.70
December 30, 2025kr 407.80
November 28, 2025kr 401.60
November 17, 2025kr 409.10

At a glance

  • The company

    Produce industrial enzymes, functional proteins, and microorganisms for food, beverage, bioenergy, cleaning, health, agriculture, and specialty applications

  • Latest results

    Quarter to September 30, 2026 · EPS €4.04 (estimate €5.31)

TickerLandia's take on Novozymes

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 336.80
52-wk highkr 484.70

−6.00% from the 52-week high

Analysts · 15 analysts

Average targetkr 510.00+11.94% vs. price

Buy 11 · Hold 4 · Sell 0 · Buy

TickerLandia Fingerprint: Novozymes

Compared with similar companies: very high price.

Financials and price compared with 59 companies in the specialty chemicals industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Novozymes is in line with similar companies

Novozymes's P/E (trailing 12 months): 42.1, in line with the median of a group of 11 similar companies (41.7).

Compared with 11 similar companies

Novozymes's metrics compared with similar companies
MetricNovozymesPosition in the groupBand
P/E (trailing 12 months)42.1Middle
Forward P/E25.9Middle
Operating margin23.4%High
ROE6.2%Middle
Debt/equity0.28Low

Grey band: the middle half of the group; tick: the median; dot: Novozymes. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€1.14B

Latest quarter · Q3 2026

Net income

€187.9M

Latest quarter · Q3 2026

Quarterly net margin

16.5%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
kr 213.94B
P/E
42.1
EPS
kr 10.91
Volume
493.73K
Daily trading
€43.79M
Dividend yield
1.45%
Last ex-dividend on August 25, 2026

How Novozymes is changing

All results
  • Revenue grew 17.2% a year on average over the last 5 years

  • Operating margin fell from 25.5% to 23.1%

  • Profits turn into cash: free cash flow equal to 139% of net income

Returns

Novozymes returns with dividends

kr 1,000 invested in Novozymes 5 years ago, on November 16, 2021, would be worth kr 961 today with dividends reinvested: −3.91% in total, −0.80% per year. On price alone it would be kr 881 (−11.91%).

PeriodNovozymeskr 1,000 becomes
1 month+0.18%kr 1,002
6 months+20.47%kr 1,205
Year to date+11.72%kr 1,117
1 year+13.28%kr 1,133
3 years+34.44%kr 1,344
5 years−3.91%kr 961
10 years+121.05%kr 2,210

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Novozymes: technical analysis

Novozymes is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 15.2% below its all-time closing high (kr 537.20, December 30, 2021).

Trend
Upward
RSI (14 sessions)
50
Between 30 and 70
vs 200-session average
+11.62%

Support and resistance

Price areas where Novozymes has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistancekr 483.10+6.04%2 touches, last on November 5, 2026
  2. Last pricekr 455.60
  3. Supportkr 432.30−5.11%2 touches, last on July 17, 2026
  4. Supportkr 426.12−6.47%6 touches, last on September 18, 2026
  5. Supportkr 409.00−10.23%3 touches, last on October 2, 2026

Volatility and risk

Volatility (60 sessions, annualised)
26.4%
Largest fall in the last year
−19.00%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Novozymes: seasonality

Average monthly price change over 26 years

−0.9%Jan+3.1%Feb+1.1%Mar+2.8%Apr+3.5%May−0.7%Jun+2.4%Jul−0.5%Aug−0.8%Sep−0.0%Oct+1.5%Nov+1.5%Dec

Over the last 26 years, the strongest month for Novozymes has been May: +3.51% on average, positive in 20 years out of 26. The weakest has been January: −0.87% on average, positive in 13 years out of 26. November, the current month, has been positive in 13 years out of 25 (+1.49% on average).

Show chart data
MonthAverageMedianPositive years
January−0.87%−0.08%13 of 26
February+3.13%+3.14%19 of 26
March+1.14%+1.65%14 of 26
April+2.79%+2.85%17 of 26
May+3.51%+3.48%20 of 26
June−0.74%−0.97%12 of 26
July+2.44%+2.18%19 of 26
August−0.47%0.00%13 of 26
September−0.75%+0.28%14 of 26
October−0.02%+1.55%14 of 26
November+1.49%+1.28%13 of 25
December+1.54%+1.69%17 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Novozymes and its competitors

Based in Lyngby, Denmark, and founded in 1925, the company develops and supplies enzymes, functional proteins and microorganisms to industrial customers. Its biosolutions serve food and beverage makers, from dairy and baking to plant-based foods, and it also supplies ethanol, biodiesel, biogas and renewable diesel producers. Other product lines cover household and industrial cleaning, human health supplements, agricultural crop and animal solutions, pet care, and leather and textile processing. Sales reach Denmark, the rest of Europe, North America, Asia Pacific, the Middle East, Africa and Latin America.

Headquarters
Lyngby, Denmark
Employees
10,933
Founded
1925
Chief executive
Ester Baiget
Novozymes and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
NovozymesNSIS.B$31.63B23.4%42.1+20.47%
DSM-FirmenichDSFIR$28.52B6.8%63.4+57.73%
SikaSIKA$36.73B13.6%29.6+38.19%
EMS-CHEMIE HOLDINGEMSN$23.88B29.9%42.3+28.25%
GivaudanGIVN$45.03B17.9%39.8+51.26%
SymriseSY1$14.06B12.6%52.6+29.50%

Same industry or related industries, similar size. Compare Novozymes with its competitors · Full profile